Nine in ten advanced cancer patients came off systemic opioids after an intrathecal pump

Design

retrospective longitudinal cohort with joint longitudinal-survival modelling for informative dropout

Population

222 patients with cancer pain receiving intrathecal drug delivery at one academic cancer centre, 2013-2023

Primary outcome

change in Brief Pain Inventory severity and interference, and physical symptom score, over 90 days

Effect

91% discontinued systemic opioids; severity -0.014 units/day (95% CI -0.020 to -0.009), interference -0.020 units/day (-0.029 to -0.011), physical symptoms -0.004 units/day (-0.006 to -0.001)

Intrathecal drug delivery in cancer pain has always had the problem that the patients who receive it are deteriorating, so any before-and-after comparison is confounded by the direction the disease is already travelling. This analysis addressed that directly: 435 patients treated at an academic cancer centre between 2013 and 2023 were screened, 222 met inclusion criteria requiring a symptom assessment within 30 days before implantation and survival beyond ten days after, and joint longitudinal-survival models were used so that death did not act as informative dropout.

Ninety-one percent discontinued systemic opioids during follow-up. Over the first 90 days after implantation, Brief Pain Inventory severity fell by 0.014 units a day (95% CI -0.020 to -0.009), interference by 0.020 units a day (-0.029 to -0.011) and the physical symptom score by 0.004 units a day (-0.006 to -0.001). Modelled separately, the pre-implantation trajectories were worsening. Mean composite scores improved at every timepoint to a year.

Daily rates are hard to feel, so convert them: 0.020 units a day of interference is roughly 1.8 points over 90 days on a 0-10 scale, which is a difference a patient notices. The modelling of the pre-implantation trajectory is what makes this more than a single-arm series - it shows the direction reversing rather than simply improving, which regression to the mean alone would not produce. It remains a single-centre retrospective cohort with no control group, and the 91% opioid discontinuation figure is the one to carry: for a patient on escalating systemic opioids with dose-limiting toxicity, this is the intervention that takes them off.

• Refer for intrathecal drug delivery earlier in advanced cancer pain, when systemic opioid escalation is producing toxicity rather than analgesia
• Quote the opioid discontinuation figure - 91% - when discussing it with a patient or an oncology team
• Set expectations over 90 days rather than days; the modelled improvement is gradual
• Note the inclusion criteria required survival beyond ten days, so this describes patients well enough to benefit
• Plan for the follow-up burden - a pump needs refilling and a service to do it

Why it matters

It reframes intrathecal delivery from a last resort to the intervention that ends systemic opioid escalation.

Don't overread it

A single-centre retrospective cohort with no control group - improvement after implantation is not proof that the implant caused it.

The statistics, in plain English

Rates expressed per day look trivially small and are not: 0.020 units a day of pain interference is about 1.8 points over the 90-day window. The joint longitudinal-survival model matters because in this population the sickest patients die, and a naive analysis would then show apparent improvement simply from losing the worst-off - that artefact is what the model removes. With no control arm, the comparison remains before-and-after within the same patients, so the effect of the pump cannot be fully separated from the effect of entering a specialist palliative service.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.